Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
CLL Society On Demand Ed Forum: ASH 2020 Comes to You – Session 3: New Combinations, New Sequences, New Ways to Measure Disease + CAR-T for Richters Recorded Thursday, February 4,
This clinical trial introduces the concept of “synthetic lethality,” where multiple targeted agents are used at low dosages to block different pathways, and achieve the ability to kill cancer cells without the associated toxicities of using three drugs together at their usual dosages.
The time-limited combination of duvelisib plus venetoclax was effective for treating relapsed / refractory CLL, but it also had significant side effects.
Hodgkin lymphoma transformation is a rare type of Richter’s transformation in which CLL / SLL turns into Hodgkin lymphoma rather than DLBCL.
Atezolizumab-venetoclax-obinutuzumab produced high remission rates, but immune-related side effects limit its usefulness as a frontline CLL therapy.
Join CLL Society and Dr. Deborah Stephens to learn how a comprehensive approach to well-being can complement your CLL care.
As more and more drugs have become available to treat CLL, doctors and patients alike want to know what is the best way to sequence these therapies.
February 2025 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Dr. Nicole Lamanna discusses upcoming novel therapies for CLL / SLL from the American Society for Hematology (ASH) annual meeting, a scientific conference.
One click to our most popular content.
